Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A 2 | Zendy

Vasilios G. Saougos | Zendy; Afroditi P. Tambaki | Zendy; M. Kalogirou | Zendy; Michael S. Kostapanos | Zendy; Irene F. Gazi | Zendy; Robert L. Wolfert | Zendy; Moses Elisaf | Zendy; Alexandros D. Tselepis | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A ₂

Author(s) -

Vasilios G. Saougos,

Afroditi P. Tambaki,

M. Kalogirou,

Michael S. Kostapanos,

Irene F. Gazi,

Robert L. Wolfert,

Moses Elisaf,

Alexandros D. Tselepis

Publication year - 2007

Publication title -

arteriosclerosis thrombosis and vascular biology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.007

H-Index - 270

eISSN - 1524-4636

pISSN - 1079-5642

DOI - 10.1161/atvbaha.107.147280

Subject(s) - fenofibrate , lipoprotein associated phospholipase a2 , rosuvastatin , ezetimibe , medicine , endocrinology , apolipoprotein b , chemistry , lipoprotein , dyslipidemia , very low density lipoprotein , lipoprotein(a) , pharmacology , cholesterol , diabetes mellitus

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a predictor for incident atherosclerotic disease. We investigated the effect of 3 hypolipidemic drugs that exert their action through different mechanisms on plasma and lipoprotein-associated Lp-PLA2 activity and mass.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research